Abstract
β-Glucans are cell wall constituents of many plants and microorganisms. However, β-glucans are not expressed on mammalian cells and are recognized as pathogen-associated molecular patterns by pattern recognition receptors. β- Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy. Recent studies have demonstrated the mechanism of action of yeast-derived β-glucan in combination with anti-tumor monoclonal antibodies in cancer therapy. in vitro and in vivo Data indicate that successful combination therapy requires complement activation and iC3b deposition on tumors and complement receptor 3 (CR3) expression on granulocytes. The defined effector cells are CR3+ neutrophils. This review provides a brief overview of this combination therapy in cancer and describes in detail the β-glucan composition and receptors, mechanism of action, and preclinical studies in human carcinoma xenograft models. Current and future developments are also discussed to provide our own point of view on this combination therapy in potential clinical investigations. Relevant patents are discussed.
Keywords: Anti-tumor monoclonal antibody, β-glucan, immunotherapy, complement receptor, neutrophils, complement regulatory proteins
Recent Patents on Anti-Cancer Drug Discovery
Title: Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer
Volume: 4 Issue: 2
Author(s): Jingjing Liu, Lacey Gunn, Richard Hansen and Jun Yan
Affiliation:
Keywords: Anti-tumor monoclonal antibody, β-glucan, immunotherapy, complement receptor, neutrophils, complement regulatory proteins
Abstract: β-Glucans are cell wall constituents of many plants and microorganisms. However, β-glucans are not expressed on mammalian cells and are recognized as pathogen-associated molecular patterns by pattern recognition receptors. β- Glucans have been used to treat cancer and infectious disease for many years as biological response modifiers with varying and unpredictable efficacy. Recent studies have demonstrated the mechanism of action of yeast-derived β-glucan in combination with anti-tumor monoclonal antibodies in cancer therapy. in vitro and in vivo Data indicate that successful combination therapy requires complement activation and iC3b deposition on tumors and complement receptor 3 (CR3) expression on granulocytes. The defined effector cells are CR3+ neutrophils. This review provides a brief overview of this combination therapy in cancer and describes in detail the β-glucan composition and receptors, mechanism of action, and preclinical studies in human carcinoma xenograft models. Current and future developments are also discussed to provide our own point of view on this combination therapy in potential clinical investigations. Relevant patents are discussed.
Export Options
About this article
Cite this article as:
Liu Jingjing, Gunn Lacey, Hansen Richard and Yan Jun, Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452858
DOI https://dx.doi.org/10.2174/157489209788452858 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alzheimer's Disease and NQO1: Is there a Link?
Current Alzheimer Research CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Biological and Genetic Features of Neuroblastoma and Their Clinical Importance
Current Pediatric Reviews Reactivity-Based Drug Discovery Using Vitamin B6-Derived Pharmacophores
Mini-Reviews in Medicinal Chemistry Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Recent Development of Peptide Drugs and Advance on Theory and Methodology of Peptide Inhibitor Design
Medicinal Chemistry The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Ginkgo biloba Extract EGb761 Attenuates Hyperhomocysteinemia-induced AD Like Tau Hyperphosphorylation and Cognitive Impairment in Rats
Current Alzheimer Research Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry Pharmacological Applications of Diphenylamine and Its Derivative as Potent Bioactive Compound: A Review
Current Bioactive Compounds Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Current Drug Metabolism Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued) An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Current Drug Targets